FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
52 letters match. Newest first.
-
BiologicsStephen J. Fallon, Ph.D.
FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.
High risk -
DrugsMaria E. De La Torre Silva, M.D.
Clinical investigator Dr. Maria E. De La Torre Silva enrolled a subject in two drug trials and kept inadequate study-drug records.
Medium -
DrugsPratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.
FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.
High risk -
DrugsJose M. Carpio, M.D.
FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.
Medium -
BiologicsAdnan Dahdul, MD
FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.
High risk -
DrugsNaseem A. Jaffrani, M.D.
FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.
High risk -
DrugsSourav K. Mishra, M.D. / All India Institute of Medical Sciences
FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.
High risk -
DrugsMukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre
FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.
High risk -
DrugsEhsan Sadri, M.D.
FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.
High risk -
DrugsBertrand P. Cole, D.O.
FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.
High risk -
DrugsMark S. Dacey, M.D.
FDA warns Dr. Mark S. Dacey that a trial subject underwent an optional eye-fluid sampling procedure after twice declining consent.
High risk -
DrugsProdrome Sciences USA, LLC
Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.
High risk -
DrugsPurushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital
FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.
High risk -
DrugsDevalingam Mahalingam, M.D., Ph.D.
FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.
High risk -
DrugsPamela K. Den Besten, DDS, MS
Clinical Investigator (Sponsor)
-
DrugsRalph A. DeFronzo, M.D.
Clinical Investigator/Sponsor
-
DrugsShirish M. Gadgeel, M.D.
Clinical Investigator
-
DrugsMark J. Savant, M.D
Clinical Investigator
-
DrugsPeter Michael, M.D.
Clinical Investigator
-
DrugsAmerican Behavioral Research Institute, LLC
Clinical Investigator (Sponsor)
-
DrugsNana Barseghian, M.D.
Clinical Investigator
-
DrugsAmerico F. Padilla, M.D.
Clinical Investigator
-
DrugsMehran Michael Bahrami, M.D.
Clinical Investigator
-
DrugsISOThrive, Inc.
Clinical Investigator
-
DrugsHan C. Phan, M.D.
Clinical Investigator
-
DrugsRichard W. Foltin, Ph.D.
Clinical Investigator (Sponsor)
-
BiologicsNamita A. Goyal, M.D.
Clinical Investigator
-
DrugsJulio R. Flamini, M.D./Clinical Integrative Research Center of Atlanta
Clinical Investigator
-
DrugsAngela D. Ritter, M.D.
Clinical Investigator (Sponsor)
-
DrugsKevin R. Bender, M.D./DBC Research Corporation
Clinical Investigator
-
DrugsBret R. Rutherford, M.D.
Clinical Investigator (Sponsor)
-
DrugsJeffrey W. Taub, M.D./Children's Hospital of Michigan
Clinical Investigator
-
DrugsAnish S. Shah, M.D./Siyan Clinical Research
Clinical Investigator
-
DrugsMelanie M. Hoppers, M.D./Physicians Quality Care
Clinical Investigator
-
DrugsMaria W. Greenwald, M.D.
Clinical Investigator
-
DrugsAntonio E. Blanco, M.D./Vista Health Research, LLC
Clinical Investigator
-
DrugsLuis Javier Pena-Hernandez, M.D., FCCP
Clinical Investigator
-
DrugsAngela M. Stupi, M.D.
Clinical Investigator
-
DrugsRandy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.
Clinical Investigator (Sponsor)
-
DrugsMobeen Mazhar, M.D.
Investigational Device Exemptions (Clinical Investigator)
-
DrugsTyrone L. McCall, M.D./Cornea Associates of Texas
Clinical Investigator (Sponsor)
-
DrugsMaggie Jeffries, M.D. / Avanti Anesthesiology, LLC
Clinical Investigator
-
DrugsAdarsh Daswani, M.D.
Clinical Investigator
-
Drugs"David M. Lubeck, M.D./Arbor Centers for EyeCare
Clinical Investigator (Sponsor)
-
DrugsSmitha C. Reddy, M.D./ACRC Studies, LLC
Clinical Investigator
-
Drugs"Daniel C. Tarquinio, D.O./Center for Rare Neurological Diseases
Clinical Investigator
-
DrugsSabine S. Hazan, M.D.
Clinical Investigator (CI)
-
DrugsRichard J. Obiso, PhD dba Avila Herbals, LLC
Clinical Investigator
-
DrugsJoseph A. Zadra, M.D.
Clinical Investigator
-
DrugsEvelyn Lopez-Brignoni, M.D.
Clinical Investigator